|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
ANTIHISTAMINES MAY DECREASE THE HAEMOSTATIC ACTION
|
ANTIHISTAMINES MAY DECREASE THE HAEMOSTATIC ACTION
|
ITRACONAZOLE REDUCES THE DRUG METABOLISM HENCE SERUM LEVELS ARE INCREASED
|
HEPARIN ACTIVITY IS REDUCED BY THE DRUG
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIHISTAMINE , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIHISTAMINE , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIHISTAMINE , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIHISTAMINE , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIHISTAMINE , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIHISTAMINE , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
CONCURRENT USE WITH H-1 RECEPTOR BLOCKER LIKE ASTEMIZOLE, ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
CONCURRENT USE WITH H-1 RECEPTOR BLOCKER LIKE ASTEMIZOLE, ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|